Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice

Overview

Journal Life (Basel)

Specialty Biology

Date 2022 Dec 23

PMID 36556402

Authors

Logan T Roberts

Peter P Issa

Evan S Sinnathamby

Mallory Granier

Holly Mayeux

Treniece N Eubanks

Kevin Malone

Shahab Ahmadzadeh

Elyse M Cornett

Sahar Shekoohi

Alan D Kaye

Affiliations

Soon will be listed here.

Abstract

Background: When prescribing antibiotics, infection eradication rates, local resistance rates, and cost should be among the most essential considerations. is among the most common infections worldwide, and it can lead to burdensome sequela for the patient and the healthcare system, without appropriate treatment. Due to constantly fluctuating resistance rates, regimens must be constantly assessed to ensure effectiveness.

Methods: This was a narrative review. The sources for this review are as follows: searching on PubMed, Google Scholar, Medline, and ScienceDirect; using keywords: , Treatment Options, Clinical Practice.

Results: Multiple antibiotics are prescribed as part of the regimen to thwart high resistance rates. This can lead to unwanted adverse reactions and adherence issues, due to the amount and timing of medication administration, which also may contribute to resistance. Single-capsule combination capsules have reached the market to ease this concern, but brand-only may be problematic for patient affordability. Due to the previously mentioned factors, effectiveness and affordability must be equally considered.

Conclusions: This review will utilize guidelines to discuss current treatment options and give cost considerations to elicit the most effective regimen for the patient.

Citing Articles

Comparative Efficacy of Azithromycin and Clarithromycin in the Management of Helicobacter pylori Infection.

Alhijazien S, Daoud S, Alzayadi M, Al Sarhan M, Aldomi M, Al Shawabkeh T Cureus. 2024; 16(10):e72033.

PMID: 39569309 PMC: 11578150. DOI: 10.7759/cureus.72033.

Liposomal Drug Delivery against Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy.

Alam M, Paget T, Yussuf Moosa N, Alghurairy H, Elkordy A Pharmaceutics. 2024; 16(9).

PMID: 39339161 PMC: 11435436. DOI: 10.3390/pharmaceutics16091123.

Optimization of Biofilm Formation in In Vitro Conditions Mimicking Stomach.

Krzyzek P, Migdal P, Krzyzanowska B, Duda-Madej A Int J Mol Sci. 2024; 25(18).

PMID: 39337326 PMC: 11432336. DOI: 10.3390/ijms25189839.

Artesunate Dry Emulsion Formulation Combined with Antibiotics for Treatment of Infections: In Vitro/In Vivo Evaluation.

Le-Tien C, Blemur L, Baltzis D Int J Mol Sci. 2023; 24(13).

PMID: 37446184 PMC: 10342150. DOI: 10.3390/ijms241311008.

Editorial: and its mechanisms of antibiotic survival.

Krzyzek P, Puca V, Grande R Front Cell Infect Microbiol. 2023; 13:1164227.

PMID: 36909728 PMC: 9996122. DOI: 10.3389/fcimb.2023.1164227.

References

Khademi F, Faghri J, Moghim S, Esfahani B, Fazeli H, Poursina F . The study of mutation in 23S rRNA resistance gene of Helicobacter pylori to clarithromycin in patients with gastrointestinal disorders in Isfahan - Iran. Adv Biomed Res. 2014; 3:98. PMC: 4007339. DOI: 10.4103/2277-9175.129368. View

Fock K, Ang T, Bee L, Lee E . Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?. Clin Pharmacokinet. 2007; 47(1):1-6. DOI: 10.2165/00003088-200847010-00001. View

Graham D . Transitioning of Therapy from Trial and Error to Antimicrobial Stewardship. Antibiotics (Basel). 2020; 9(10). PMC: 7601139. DOI: 10.3390/antibiotics9100671. View

Butt A, Sarwar S, Nadeem M . Concomitant Therapy versus Triple Therapy: Efficacy in H. Pylori Eradication and Predictors of Treatment Failure. J Coll Physicians Surg Pak. 2021; 31(2):128-131. DOI: 10.29271/jcpsp.2021.02.128. View

PETERSON W, Graham D, Marshall B, Blaser M, Genta R, KLEIN P . Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol. 1993; 88(11):1860-4. View

Katiyar S, Edlind T . Enhanced antiparasitic activity of lipophilic tetracyclines: role of uptake. Antimicrob Agents Chemother. 1991; 35(11):2198-202. PMC: 245359. DOI: 10.1128/AAC.35.11.2198. View

Gisbert J, Pajares J . Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter. 2004; 9(4):347-68. DOI: 10.1111/j.1083-4389.2004.00235.x. View

Goderska K, Agudo Pena S, Alarcon T . Helicobacter pylori treatment: antibiotics or probiotics. Appl Microbiol Biotechnol. 2017; 102(1):1-7. PMC: 5748437. DOI: 10.1007/s00253-017-8535-7. View

Vilaichone R, Prapitpaiboon H, Gamnarai P, Namtanee J, Wongcha-Um A, Chaithongrat S . Seven-Day Bismuth-based Quadruple Therapy as an Initial Treatment for Helicobacter pylori Infection in a High Metronidazole Resistant Area. Asian Pac J Cancer Prev. 2015; 16(14):6089-92. DOI: 10.7314/apjcp.2015.16.14.6089. View

10.

Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M . Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016; 65(9):1439-46. PMC: 5036253. DOI: 10.1136/gutjnl-2015-311304. View

11.

Garza-Gonzalez E, Perez-Perez G, Maldonado-Garza H, Bosques-Padilla F . A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol. 2014; 20(6):1438-49. PMC: 3925853. DOI: 10.3748/wjg.v20.i6.1438. View

12.

Roberts M . Tetracycline therapy: update. Clin Infect Dis. 2003; 36(4):462-7. DOI: 10.1086/367622. View

13.

Li B, Threapleton D, Wang J, Xu J, Yuan J, Zhang C . Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015; 351:h4052. PMC: 4541168. DOI: 10.1136/bmj.h4052. View

14.

Kim S, Choi D, Chung J . Antibiotic treatment for Helicobacter pylori: Is the end coming?. World J Gastrointest Pharmacol Ther. 2015; 6(4):183-98. PMC: 4635158. DOI: 10.4292/wjgpt.v6.i4.183. View

15.

Saracino I, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T . Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection. Eur J Intern Med. 2020; 81:50-53. DOI: 10.1016/j.ejim.2020.06.029. View

16.

Abraham N . Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012; 28(6):615-20. DOI: 10.1097/MOG.0b013e328358d5b9. View

17.

Nishizawa T, Suzuki H . Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing. Front Mol Biosci. 2015; 1:19. PMC: 4428472. DOI: 10.3389/fmolb.2014.00019. View

18.

Greenberg E, Anderson G, Morgan D, Torres J, Chey W, Bravo L . 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011; 378(9790):507-14. PMC: 3313469. DOI: 10.1016/S0140-6736(11)60825-8. View

19.

Saleem N, Howden C . Update on the Management of Infection. Curr Treat Options Gastroenterol. 2020; 18(3):476-487. PMC: 7365691. DOI: 10.1007/s11938-020-00300-3. View

20.

Gisbert J, Romano M, Gravina A, Solis-Munoz P, Bermejo F, Molina-Infante J . Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015; 41(8):768-75. DOI: 10.1111/apt.13128. View